According to PitchBook’s 2021 U.S. Venture Capital Outlook report, biotech and pharma VC deal activity will probably exceed $20 billion during 2021.

Four more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.  

President Donald Trump signed an Executive Order that ensures the U.S. government prioritizes delivery of Covid-19 vaccines to American citizens before sending them to other nations.

Regenerative medicine company AVITA Therapeutics Inc. announced the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.

MacroGenics Inc. announced a partnership with Eversana to commercialize margetuximab in the United States, if approved.

Lilly

Eli Lilly and Company and Precision BioSciences Inc. announced a research collaboration and exclusive license agreement to use Precision’s ARCUS genome editing platform to research and develop potential in vivo therapies for a series of genetic disorders.

BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period

The Healthcare Technology Report announced the Top 25 Women Leaders in Biotechnology of 2020.

The Covid-19 pandemic changed the biopharma industry and the world irrevocably, and the challenges will reverberate even after the pandemic ends, according to some health experts.

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.